Strong sector and stage alignment (computational drug discovery in pharma/therapeutics), but critical geographic mismatch. Biomedical Catalyst requires UK-based businesses; applicant is targeting EU (Île-de-France priority) and lists UK as secondary. Unless the venture incorporates in UK and establishes UK presence, this program is misaligned with stated geographic strategy.